An open-label phase 1 study to evaluate pharmacokinetic/pharmacodynamic drug-drug interactions and safety/tolerability of DWC202211 and DWC202212 compared to coadministration in healthy
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
24
DWC202211 for 5 days Aspirin 100mg
DWC202212 for 3 days Rabeprazole 5mg
DWC202211 + DWC202212 for 5 days Aspirin 100mg, Rabeprazole 5mg
Seoul National University Hospital
Seoul, South Korea
Cmax
Time frame: up to 27 days
AUClast
Time frame: up to 27 days
DWC202211 Tmax,ss
Time frame: up to 27 days
DWC202211 T1/2,ss
Time frame: up to 27 days
DWC202211 Cmin,ss
Time frame: up to 27 days
DWC202211 Cavg,ss
Time frame: up to 27 days
DWC202211 CLss/F
Time frame: up to 27 days
DWC202211 Vdss/f
Time frame: up to 27 days
DWC202211 PTF
Time frame: up to 27 days
DWC202212 Tmax,ss
Time frame: up to 27 days
DWC202212 T1/2,ss
Time frame: up to 27 days
DWC202212 Cmin,ss
Time frame: up to 27 days
DWC202212 Cavg,ss
Time frame: up to 27 days
DWC202212 CLss/F
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: up to 27 days
DWC202212 Vdss/f
Time frame: up to 27 days
DWC202212 PTF
Time frame: up to 27 days